Angiogenesis regulated by VEGF and its receptors and its clinical application

Rinsho Ketsueki. 2009 May;50(5):404-12.
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors*
  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents*
  • Benzenesulfonates
  • Bevacizumab
  • Drug Design*
  • Humans
  • Indoles
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplastic Cells, Circulating
  • Neovascularization, Pathologic / genetics*
  • Neovascularization, Physiologic / genetics
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / immunology
  • Receptors, Vascular Endothelial Growth Factor / physiology*
  • Recombinant Fusion Proteins
  • Signal Transduction
  • Sorafenib
  • Sunitinib
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / immunology
  • Vascular Endothelial Growth Factor A / physiology*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Niacinamide
  • Bevacizumab
  • Sorafenib
  • Receptors, Vascular Endothelial Growth Factor
  • Sunitinib